PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma

Mantle cell lymphoma (MCL) is an incurable B-cell malignancy that comprises up to 6% of non-Hodgkin lymphomas diagnosed annually and is associated with a poor prognosis. The average overall survival of patients with MCL is 5 years, and for most patients who progress on targeted agents, survival rema...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown-Burke, Fiona, Hwang, Inah, Sloan, Shelby, Hinterschied, Claire, Helmig-Mason, JoBeth, Long, Mackenzie, Chan, Wing Keung, Prouty, Alexander, Chung, Ji-Hyun, Zhang, Yang, Singh, Satishkumar, Youssef, Youssef, Bhagwat, Neha, Chen, Zhengming, Chen-Kiang, Selina, Di Liberto, Maurizio, Elemento, Olivier, Sehgal, Lalit, Alinari, Lapo, Vaddi, Kris, Scherle, Peggy, Lapalombella, Rosa, Paik, Jihye, Baiocchi, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582835/
https://www.ncbi.nlm.nih.gov/pubmed/37327122
http://dx.doi.org/10.1182/bloodadvances.2023009906

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582835/
https://www.ncbi.nlm.nih.gov/pubmed/37327122
http://dx.doi.org/10.1182/bloodadvances.2023009906

Ejemplares similares